This is our mock oral boards for lower GI malignancies. I will present two comprehensive rectal cancer cases, walking you through each one from initial presentation all the way through treatment and follow-up. For each section, I want you to pause and formulate your own structured response before I walk you through the model answer and a key teaching pearl. The goal is to think like an attending and solidify your clinical decision-making from start to finish. Let's get started.

Over the last several episodes, we've systematically broken down the evidence that defines modern GI oncology. Today, we put that knowledge to the test. This episode is a mock oral board examination. I will present five comprehensive case blocks, covering Esophageal, Gastric, Pancreatic, Hepatobiliary, and Hepatocellular cancers. For each, I will present a clinical scenario and then pose a series of questions designed to test your knowledge across all core competencies. Pause after each question to formulate your own structured response before I provide the model answer and a key teaching pearl. Let's begin.

This episode is a mock oral boards session. I will present three distinct, challenging clinical scenarios. For each case, we will walk through the entire management process, from initial presentation all the way through treatment and follow-up, to sharpen your clinical decision-making.

Over the past decade, the landscape of systemic therapy has been transformed by the arrival of immunotherapy and highly effective targeted agents. Many of these drugs have significant intracranial activity, creating a new and complex challenge for the radiation oncologist: how do we sequence our treatments? The old paradigm of "radiation first" is no longer always correct. Today, we will provide a modern guide to navigating this new reality. We will discuss when it's appropriate to defer radiation entirely, compare the CNS efficacy of different systemic regimens, and detail the critical safety considerations and toxicity risks of combining SRS with these powerful new drugs.

Today, we address the frontiers of SRS. First, we'll ask: can we treat more than four metastases? Second, how do we safely and effectively treat large metastases that are too big for a single high dose of radiation? And finally, we will tackle the most common and challenging complication of SRS: how to differentiate radiation necrosis from tumor progression.

Today, we will conduct a practical workshop on postoperative stereotactic radiosurgery. We'll dissect the two landmark trials that define this practice, learn how to properly delineate a post-operative target volume, and discuss the dreaded complication of nodular leptomeningeal disease.

In our last episode, we laid the groundwork for managing brain metastases. Today, we tackle one of the most significant paradigm shifts in modern radiation oncology: the move away from routine whole-brain radiotherapy for patients with a limited number of brain metastases. For decades, WBRT was the standard. Now, for many patients, it's an inferior option. We will walk through the chronological story of the landmark trials that drove this revolution, culminating in the definitive evidence that establishes stereotactic radiosurgery, or SRS, alone as the standard of care for preserving cognitive function.

Brain metastases are the most common intracranial tumor in adults, and their management has undergone a complete revolution. Before we can treat, we must be able to prognosticate and have a firm grasp of the foundational principles. Today, we will cover the essential background, including epidemiology and workup. We will master the modern prognostic indices, including the Disease-Specific Graded Prognostic Assessment, or D-S-G-P-A. And finally, we will open the whole-brain radiotherapy toolkit, discussing the evidence for adding memantine and detailing the technique and landmark data for hippocampal-avoidance WBRT.

This is Episode 8: Low-Grade Glioma Part 3: Treatment Planning & Case-Based Review. Over the last two episodes, we've built the complete evidence-based framework for managing WHO Grade II gliomas. We've learned how to risk-stratify patients, when to treat, and what regimen to use. Today, we put that knowledge into practice. We'll start with a deep dive into the technical details of treatment planning and toxicity management. Then, we will consolidate our knowledge by working through a series of challenging, oral board-style case scenarios designed to test your clinical decision-making from start to finish.

This is Episode 7: Low-Grade Glioma Part 2: Evidence for Chemo, Dose, and IDH Inhibitors.In our last episode, we established the framework for managing Grade II gliomas, answering the crucial question of when to treat. Today, we address the next logical question: for those high-risk patients we decide to treat, how do we treat them? We will dissect the pivotal evidence that transformed our approach from radiation alone to combined-modality therapy, justify our standard radiation dose by looking at the specific data from the negative dose-escalation trials, and look to the future with the exciting new data on targeted IDH inhibitors.